Related Experiment Videos
Clinical experience and management considerations with long-acting risperidone
1Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, Spain. eparella@clinic.ub.es
Current Medical Research and Opinion
|February 10, 2006
Summary
Long-acting risperidone offers effective and well-tolerated treatment for schizophrenia, benefiting diverse patient groups. This formulation improves compliance and aids in achieving remission for better functional recovery.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Risperidone is the first atypical antipsychotic available in a long-acting injectable formulation.
- Initial clinical experience with long-acting risperidone was evaluated during clinical trials and general treatment.
Observation:
- Literature searches (Medline, EMBASE) and congress abstracts (2002-2005) were reviewed for pharmacokinetic, efficacy, and safety data.
- The review included studies on long-acting risperidone for schizophrenia treatment.
Findings:
- Long-acting risperidone (25, 37.5, 50 mg every 2 weeks) is effective and well-tolerated in schizophrenia patients.
- Significant clinical improvement was observed in patients switched from other antipsychotics.
- Young, elderly, and schizoaffective disorder patients showed significant benefits.
Implications:
- Long-acting risperidone benefits various patient groups, including those with suboptimal efficacy or side effects from other agents.
- Assured medication delivery enhances patient compliance.
- Improved compliance facilitates remission and functional recovery in schizophrenia patients.